Drugs / NGGT003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06238908 | Jan 2024 → Jan 2026 overdue | hemophilia A | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGGT003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06238908 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “NGGT003 uses adeno-associated virus (AAV) as a vector” NCT06238908 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06238908 ↗ |